GeneDx Appoints Lisa Gurry as Chief Business Officer to Unlock Data and Information Growth

GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced the appointment of Lisa Gurry as Chief Business Officer (CBO), effective immediately. In this newly-created role, Gurry will lead GeneDx’s next phase of transformation, advancing data and information services across biopharma, health systems, and other partners to accelerate the company’s long-term vision of enabling precision medicine.

As Chief Business Officer, Gurry will architect and operate GeneDx’s strategic business operations and partnership models that open doors and create opportunities to unlock the full potential of GeneDx Infinity, the largest rare disease dataset, with nearly one million exomes and genomes paired with more than seven million phenotypic datapoints. Unmatched in depth and diversity, GeneDx Infinity is already powering faster and more accurate diagnoses for families and enabling biopharma partners to accelerate drug discovery and development. Gurry will also oversee communications for GeneDx and partner on market growth strategies.

“As the largest provider of rare disease diagnosis in the world, GeneDx is uniquely positioned to enable drug discovery and development, fueling the future of precision medicine with the most enriched genomic insights. As we enter our next phase of growth, Lisa’s world-class leadership in data commercialization, partnerships, and go-to-market execution is exactly what we need to unlock the full potential of genomic data,” said Katherine Stueland, President and CEO of GeneDx. “With the power of GeneDx Infinity, Lisa will help us drive value and better patient outcomes by delivering genomic insights across health systems and biopharma.”

With deep expertise at the intersection of healthcare, technology, and data, Gurry brings a proven track record of turning bold ideas into scaled businesses. She co-founded Truveta, where she built the growth engine that helped to deliver strategic partnerships with more than 100 organizations across life sciences, healthcare, public health, and academic research. Prior to Truveta, Gurry spent over two decades at Microsoft driving global growth strategies for Windows, Office, and Xbox.

“GeneDx has built something extraordinary: an innovative dataset with the power to change the trajectory of medicine infused with clinical expertise for clarity and action,” said Gurry. “By combining the scale of GeneDx Infinity with the urgency of our mission, we can accelerate diagnoses for families, fuel drug discovery for biopharma, and deliver data-powered value to health systems. I am honored to join this incredible team and empower patients and their families with answers that transform lives.”